Product Program year 2025 Source: CMS Open Payments

Xacduro

Drug Infectious Disease

NDC 68547-111-10

Open in the dashboard

General payments

$204,227

1,259 payments

Research payments

$615,702

49 payments

Through program year 2025, $204,227 in general payments and $615,702 in research payments were reported against Xacduro (Infectious Disease).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2025 General $53,050 432
2025 Research $341,443 38
2024 General $116,591 713
2024 Research $159,100 5
2023 General $34,586 114
2023 Research $115,159 6

Breakdown

Who paid General payments · program years 2023–2025
  1. La Jolla Pharmaceutical Company $204,227 1,259 payments
Top recipients General payments · program year 2025
  1. Rajkumar Dasgupta Pulmonary Disease · Pasadena, CA $9,894 19% · 1 payment
  2. Juan Diaz Infectious Disease · Altamonte Springs, FL $6,014 11% · 8 payments
  3. Fares Khater Internal Medicine · Whitesburg, KY $4,178 8% · 5 payments
  4. Mayo Clinic Hospital Teaching hospital · AZ $2,900 5% · 1 payment
  5. Jason Sniffen Infectious Disease · Altamonte Springs, FL $2,662 5% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Infectious Disease Internal Medicine $19,063 44% · 143 practitioners
  2. Pulmonary Disease Internal Medicine $10,013 23% · 5 practitioners
  3. Internal Medicine $5,657 13% · 24 practitioners
  4. Pediatric Infectious Diseases Pediatrics $2,182 5% · 2 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $1,067 2% · 24 practitioners

The top 5 of 34 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. California $13,719 26% · 35 recipients
  2. Florida $12,572 24% · 39 recipients
  3. Kentucky $4,794 9% · 12 recipients
  4. Texas $3,094 6% · 18 recipients
  5. Arizona $3,011 6% · 4 recipients

The top 5 of 31 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

1,259 general · 49 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record